6th Annual Project & Portfolio Management in the Pharmaceutical Industry

Jacob Fleming Conferences28 - 29 September 2010, Milan, Italy.
After 5 successful annuals and the industry feedback, Jacob Fleming Conferences is bringing a well-balanced program full of real life case studies on major achievements in Project & Portfolio Management Approaches established across leading Pharma companies.

Testimonials
"Good balance of speakers, great learning experience and excellent chairman!"
Director Research Project Management, MedImmune, UK

"Very high-quality & influential speakers."
Portfolio Director, AstraZeneca, UK

"Very practical, inspiring and high-level agenda. Very good conclusions from the chairman."
Senior Portfolio Manager, GlaxoSmithKline, Belgium

Expert Advisors
Head of Discovery Research, Roche, Switzerland
Vice President Portfolio Management, Strategic Planning, Bayer Schering Pharma, Germany
Vice President Project Management R&D, Amgen, USA
Scientific Vice President, Novo Nordisk, Denmark
Head R&D Portfolio Management, UCB, UK
Executive Vice President & Chief Scientific Officer, Ipsen, France
Executive Vice President Research & Development, Nycomed, Germany

Key speakers
Vice President Special Operations, Worldwide Research Centers of Emphasis, Pfizer, UK
Global Head Portfolio Management & Reporting, Sanofi Aventis, France
Head Global Project Management, Abbott, Germany
Global Head of Portfolio Management & Interfaces Discovery Research and Oncology, MerckSerono, Switzerland
Head Portfolio Management, Bayer Schering Pharma, Germany
Vice President Research, Lundbeck, Denmark
Senior Project Leader Cancer Immunotherapeutics, GSK Biologicals, Belgium

Key topics

  • Explore the ways how leading Pharma companies develop their portfolios to add value to key stakeholders
  • Trends in portfolio offerings – more for physicians, payers or patients?
  • The impact of current payer-driven environment and cost-containment initiatives on managing R&D projects
  • Achieving a balanced, rich & varied portfolio in a competitive and limited resources environment
  • Innovative approaches to managing Discovery Projects
  • Project Management in Late stage Development Projects
  • Prioritization and decision analysis tools –decision making on innovation
  • Balancing the risks in Project & Portfolio Management - Risk Management in PPM
  • Enhancing the innovation & strong portfolios through R&D collaborations and M&A – the role of alliance management & business development

Who should attend
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Portfolio Management, Project Management, Pharmaceutical Development, R&D, Strategic Planning & Decision, Strategy & Portfolio Analysis, Portfolio Selection, Decision Analysis.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6thPPM?partner=worldpharmanewsPPM

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...